Sotera Health Company (SHC)
NEUTRALFundamental
58
Price
$19.54
Market Cap
$5.48B
Part 1 · What the company is worth
Overview
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.22B
Trailing 12 months (through 6/30/2026)
Net Income
$163M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$149M
Total Equity
$606M
Total Liabilities
$2.66B
Current Ratio
2.80
Interest Coverage
-
Debt/EBITDA
3.93
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$13.10
Current Price
$19.54
Margin of Safety
-49.1%
Fair Value Range
$8.52 - $17.69
Estimation Methods
Valuation Metrics
P/E Ratio
33.63
ROE
12.9%
P/B Ratio
8.22
P/FCF
48.54
Gross Margin
55.0%
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
10.4%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (13)
- EPS shows upward trend
- Gross Margin 55.0%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 20.6%
- Revenue Growth 5Y 7.3%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 8.4%
- Earnings Quality (OCF/NI) 1.79
- Net Margin Trend 13.4% vs 2.1%
- Piotroski F-Score 6/9
Failed (9)
- Price CAGR -5.48%
- P/FCF 48.54
- P/B Ratio 8.22
- Debt/Equity ratio
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 4.0%
Unavailable (5)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Michael B. Petras Jr. | Executive Chairman of the Board | 56 |
| Mr. Jonathan M. Lyons | Senior VP & CFO | 47 |
| Mr. Michael P. Rutz | President of Sterigenics U.S., LLC | 54 |
| Mr. Alton E. Shader | CEO & Director | 52 |
| Mr. Robert G. Hauzie | Chief Information Officer | - |
| Ms. Erika Ostrowski | Senior VP, General Counsel & Corporate Secretary | - |
| Ms. Kristin A. Gibbs | Chief Marketing Officer | - |
| Mr. William O. Lehmann Jr., J.D., M.B.A. | Senior Vice President of Strategy & Corporate Development | 59 |
| Ms. Sally R. Turner | Chief Human Resources Officer | - |
| Ms. Danielle J. Menture | Senior Vice President of Global Environmental, Health & Safety and Sustainability | - |
Audit Risk
4
Board Risk
7
Compensation Risk
5
Shareholder Rights Risk
7
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for SHC, sourced from Markets Gazette.
- 3/15/2026NEUTRALSotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals
Sotera Health Company shares have seen an 18% increase over the past year, with recent activity indicating a significant stake trim by an insider amounting to $37 million. Sotera Health provides crucial sterilization and laboratory testing services to highly regulated industries globally, playing a vital role in maintaining essential supply chains. While the stock has performed well, the substantial insider sale could signal a divergence of opinion on future valuation or a need for liquidity, warranting investor attention.
- 3/2/2026NEGATIVESotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?
Sotera Health, a global provider of sterilization and laboratory solutions to the healthcare, pharmaceutical, and food industries, has seen an impressive 30% growth over the past year. Despite this robust performance, an unidentified fund divested $4 million worth of shares. This move raises questions among investors: why would an institutional entity sell such a significant stake in a rapidly growing company? It could signal strategic profit-taking, a portfolio rebalancing, or potentially a less optimistic view on the company's future prospects not yet apparent to the broader market. Investors should closely monitor upcoming developments and the rationale behind this significant divestment.
- 2/24/2026NEUTRALInsights into Sotera Health Q4 Earnings
Investors are keenly awaiting insights into Sotera Health's fourth-quarter earnings, a pivotal event for assessing the company's performance and future outlook. Analyzing quarterly results is crucial for understanding financial health, revenue growth, and profitability, all of which directly influence market sentiment and investment decisions. While specific details are yet to be disclosed, market focus remains on how Sotera Health navigated operational challenges and opportunities during the period. Key data points, such as revenue, earnings per share (EPS), and future guidance, will be scrutinized to identify trends and potential catalysts for the stock price. Results meeting or exceeding expectations could bolster confidence, whereas a disappointment might trigger a negative reaction.
via Markets Gazette